Re: Amended and Restated Employment Terms Dear Jen:Employment Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 29th, 2021 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment in connection with your appointment as Chief Financial Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of February 1, 2021 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. effective January 1, 2019 (the “Prior Agreement”).
Re: Amended and Restated Employment Terms Dear Lou:Employment Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 29th, 2021 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment in connection with your appointment as Chief Executive Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of February 1, 2021 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. effective January 1, 2019 (the “Prior Agreement”).
February 5, 2020 Christophe Arbet-Engels Wellesley, MA 02481 Re: Employment TermsEmployment Agreement • March 11th, 2020 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 11th, 2020 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) is pleased to offer you employment in the position of Chief Medical Officer of the Company pursuant to the terms of this letter (the “Agreement’’). Subject to your execution of this Agreement, the terms herein will be effective as of February 10, 2020 (the “Effective Date”).
August 16, 2019Employment Agreement • November 13th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 13th, 2019 Company Industry
July 11, 2019Employment Agreement • November 13th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 13th, 2019 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) is pleased to offer you employment in the position of General Counsel of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, the terms herein will be effective as of August 19, 2019 (the “Effective Date”).
June 19, 2019 Louis Arcudi III Hopedale, MA 01747 Re: Amended and Restated Employment Terms Dear Lou:Employment Agreement • August 12th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2019 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment as the Chief Financial Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of January 1, 2019 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. (formerly known as Millendo Therapeutics, Inc.) dated November 1, 2018 (the “Prior Agreement”).
May 21, 2019 Jeffery M. Brinza Brighton, MI 48116 Re: Amended and Restated Employment Terms Dear Jeffery:Employment Agreement • August 12th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2019 Company IndustryMillendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment as the Chief Administrative Officer and General Counsel of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of January 1, 2019 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. (formerly known as Atterocor, Inc.) dated July 28, 2015 (the “Prior Agreement”).